Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs

ABSTRACT

The recent outbreak of pneumonia caused by new coronavirus (SARS-CoV-2) infection has brought major challenges to public health and governance in various countries. At present, there is no clinically specific drug for SARS-CoV-2, and most of the antiviral drugs used are drugs for the treatment of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This article aims to organize and analyze the antiviral drugs and their pharmacokinetic characteristics, and to discuss the characteristics and necessity of therapeutic drug monitoring (TDM), so as to provide a reference for the safety of anti-SARS-CoV-2 treatment.